Retension Pharmaceuticals' Q3 net loss widens to $5.92M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Retension Pharmaceuticals, Inc. reported a third-quarter net loss of $5,918,084, compared with $1,475,814 a year earlier, while research and development expense was $5,016,602 versus $1,365,256. Cash and cash equivalents were $9,190,083 as of September 30, 2026.
The company completed an October initial public offering of 4,312,500 shares at $12.00 each, generating gross proceeds of $51.75 million and approximately $45.1 million in net proceeds. Its Phase 2b RTN-001 trial is evaluating approximately 280 patients with uncontrolled hypertension; topline data are expected in the first half of 2027. The study will also inform dose selection for Phase 3.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Moderate pointQuarterly net loss increased to $5,918,084 from $1,475,814.
8-K Event Classification
Key Figures
Key Terms
dose-ranging trial medical
primary endpoint medical
office-seated systolic blood pressure medical
PDE5 inhibitor medical
nitric oxide signaling technical
Earnings Snapshot
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Retension Pharmaceuticals (RTSN)’s third-quarter 2026 results?
How much did Retension (RTSN) receive from its October 2026 IPO?
What is the primary endpoint of Retension’s (RTSN) RTN-001 Phase 2b trial?
AI-generated analysis. How Rhea-AI works. Not financial advice.